Table 1.
—Drugs Reported to Cause DALI and Their Frequency of Application Within the Cohort
| Drug | No.a | Drug | No.a |
| Amiodarone | 14 | Leuprorelin | 0 |
| Arsenic trioxide | 0 | Medroxyprogesterone | 0 |
| Basiliximab | 0 | Melphalan | 2 |
| Bleomycin | 3 | Methotrexate | 11 |
| Busulfan | 0 | Mitomycin C | 1 |
| Carmustine (BCNU) | 1 | Nitrofurantoin | 0 |
| Cyclophosphamide | 10 | Muromunab-CD3 | 0 |
| Cyclosporine | 4 | Oxaliplatin | 1 |
| Cytarabine | 5 | Paclitaxel | 3 |
| Docetaxel | 0 | Pentostatin | 0 |
| Doxorubicin | 8 | Recombinant GM-CSF | 0 |
| Fludarabine | 1 | Rituximab | 4 |
| Gefitinib | 0 | Teniposide (VM-26) | 0 |
| Gemcitabine | 2 | Tretinoin/retinoic acid | 0 |
| Gold salts | 0 | Tumor necrosis factor | 0 |
| Immunglobulin | 0 | Vinblastine | 3 |
| Infliximab | 1 | Vincristine | 5 |
| IL-2 | 0 | Vindesine | 0 |
| Irinotecan | 3 | Vinorelbine | 0 |
DALI = drug-associated acute lung injury; GM-CSF = granulocyte monocyte colony-stimulating factor.
a
Frequency of application.